P580: Upadacitinib is effective and safe for Ulcerative Colitis: prospective real-world experienceECCO’23 CopenhagenYear: 2023
Authors: Friedberg, S.(1)*;Choi, D.(1);Hunold, T.(1);Choi, N.K.(1);Garcia, N.M.(1);Picker, E.A.(1);Cohen, N.A.(1);Cohen, R.D.(1);Dalal, S.R.(1);Pekow, J.(1);Sakuraba, A.(1);Krugliak Cleveland, N.(1);Rubin, D.T.(1);
(1)University of Chicago, Inflammatory Bowel Disease Center, Chicago, United States;
P581: Early biological therapy within the first 12 months after diagnosis leads to higher clinical, endoscopic, and transmural remission in Crohn's disease: European multicentre study with a propensity-score matched analysisECCO’23 CopenhagenYear: 2023
Authors: Revés, J.(1)*;Fernandez-Clotet, A.(2);Ordás, I.(2);Buisson, A.(3);Ellul, P.(4);Elorza, A.(5);Aduna, M.(6);Rodríguez-Lago, I.(5);Freire, G.(7);Sousa, P.(7);Primitivo, A.(7);Delgado, I.(7);Sousa Lajas, I.(8);Raimundo, A.(8);Bettencourt, P.(8,9);Rimola, J.(10);Torres, J.(1,11);
(1)Hospital Beatriz Ângelo, Gastroenterology Department, Loures, Portugal;(2)Hospital Clínic de Barcelona- Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS- and CIBEREHD, Department of Gastroenterology, Barcelona, Spain;(3)Université Clermont Auvergne- Inserm- CHU Clermont-Ferrand, Department of Gastroenterology, Clermont-Ferrand, France;(4)Mater Dei Hospital, Division of Gastroenterology, Msida, Malta;(5)Hospital Universitario de Galdakao, Department of Gastroenterology, Galdakao, Spain;(6)OSATEK-hospital de Galdakao, Department of Radiology, Galdakao, Spain;(7)Hospital Beatriz Ângelo, Department of Radiology, Loures, Portugal;(8)Universidade Católica Portuguesa, Faculty of Medicine, Rio de Mouro, Portugal;(9)Universidade Católica Portuguesa, Centre for Interdisciplinary Research in Health, Lisbon, Portugal;(10)Hospital Clínic de Barcelona- IDIBAPS, Department of Radiology, Barcelona, Spain;(11)University of Lisbon, Faculty of Medicine, Lisbon, Portugal;
P582: Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trialECCO’23 CopenhagenYear: 2023
Authors: Vermeire, S.(1)*;Sands, B.E.(2);Dubinsky, M.C.(3);Feagan, B.G.(4);Panaccione, R.(5);Jairath, V.(6);Yarur, A.(7);Chiorean, M.(8);Panés, J.(9);Goetsch, M.(10);Rabbat, C.J.(11);Shah, P.(12);Wu, J.(13);Ghosh, S.(14);
(1)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;(2)Dr. Henry D. Janowitz Division of Gastroenterology- Icahn School of Medicine at Mount Sinai, Gastroenterology, New York- New York, United States;(3)Feinstein IBD Center- Mount Sinai, Gastroenterology, New York- New York, United States;(4)University of Western Ontario/Alimentiv Inc, Gastroenterology, London- Ontario, Canada;(5)Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology- University of Calgary, Gastroenterology and Hepatology, Calgary- Alberta, Canada;(6)Western University, Gastroenterology, London- Ontario, Canada;(7)Cedars-Sinai Medical Center, Gastroenterology, Los Angeles- California, United States;(8)IBD Center- Swedish Medical Center, Gastroenterology, Seattle- Washington, United States;(9)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;(10)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(11)Pfizer Inc, Global Medical Affairs- Gastroenterology, New York- New York, United States;(12)Pfizer Inc, US Medical Affairs- Inflammation & Immunology, Collegeville- Pennsylvania, United States;(13)Pfizer Inc, Biostatistics, Groton- Connecticut, United States;(14)College of Medicine and Health- University College Cork, Gastroenterology, Cork, Ireland;
P584: Efficacy, safety, and tolerability of AMT-101, a gut selective oral IL-10 fusion, in the Phase 2 FILLMORE trial of patients with chronic pouchitisECCO’23 CopenhagenYear: 2023
Authors: Jairath, V.(1)*;Bressler , B.(2);Silverberg , M.S.(3);Lee, L.Y.(4);Lugo, K.A.(4);Mayoral Monibas, R.(4);Annamalai, T.(4);Whitney, J.A.(4);Weng, E.Y.(4);Kanwar, B.(4);Danese , S.(5);Feagan, B.(1);
(1)Western University, Division of Gastroenterology, London- Ontario, Canada;(2)University of British Columbia, Division of Gastroenterology, Vancouver, Canada;(3)Mount Sinai Hospital- University of Toronto, Division of Gastroenterology, Toronto, Canada;(4)Applied Molecular Transport, Applied Molecular Transport, South San Francisco, United States;(5)University Vita-Salute San Raffaele, Division of Gastroenterology, Milan, Italy;
P585: Duration of response to ozanimod after treatment withdrawal: results from the phase 3 True North studyECCO’23 CopenhagenYear: 2023
Authors: Vermeire, S.(1)*;Abraham, B.(2);Bressler, B.(3);Reinisch, W.(4);Jain, A.(5);Memaj, A.(5);Akukwe, L.(5);Liu, W.J.(5);Osterman, M.(5);Canavan, J.B.(5);Sands, B.E.(6);
(1)University Hospitals Leuven, Chronic Diseases and Metabolism, Leuven, Belgium;(2)Houston Methodist Academic Institute, Gastroenterology, Houston, United States;(3)University of British Columbia, Medicine, Vancouver- BC, Canada;(4)Medical University of Vienna, Gastroenterology and Hepatology, Vienna, Austria;(5)Bristol Myers Squibb, Clinical Research, Princeton, United States;(6)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;
P586: Vedolizumab in Mild to Moderate Crohn's Disease Patients Naïve to Biological Therapy: a Multicentric Observational StudyECCO’23 CopenhagenYear: 2023
Authors: Dotti, A.Z.(1);Vilela, E.G.(2);Chebli, J.M.F.(3);Chebli, L.A.(4);Magro, D.O.(5);Steinwurz, F.(6);Argollo, M.(7);Carvalho, N.S.(7);Parente, J.M.L.(8);Parra, R.S.(9);Perin, R.L.(10);Flores, C.(11);Morsoletto, E.M.(12);Ferreira, S.D.C.(13);Ludvig, J.C.(14);Kaiser Jr, R.L.(15);Queiroz, N.S.F.(16);Faria, M.A.G.(17);Nicollelli, G.M.(18);Andrade, A.R.(19);KotzeMD- PhD, P.G.(20)*;
(1)Universidade Federal do Paraná, Gastroenterology, Curitiba, Brazil;(2)Universidade Federal de Minas Gerais UFMG, Gastroenterology, Belo Horizonte, Brazil;(3)Universidade Federal de Juiz de Fora, Gastroewnterology, Juiz de Fora, Brazil;(4)Universidade Federal de Juiz de Fora, Gastroenterology, Juiz de Fora, Brazil;(5)University of Campinas UNICAMP, Colorectal Surgery, Campinas, Brazil;(6)Hospital Israelita Albert Einstein, Gastroenterology, Sao Paulo, Brazil;(7)Sao Luiz Hospital, Gastroenterology, Sao Paulo, Brazil;(8)Universidade Federal do Piaui, Gastroenterology, Teresina, Brazil;(9)Universidade de Sao Paulo, Colorectal Surgery, Ribeirao Preto, Brazil;(10)Universidade de Passo Fundo, Colorectal Surgery, Passo Fundo, Brazil;(11)Instituto do Aparelho Digestivo, Gastroenterology, Porto Alegre, Brazil;(12)Hospital Sao Vicente, Gastroenterology, Curitiba, Brazil;(13)Universidade de Sao Paulo, Gastroenterology, Ribeirao Preto, Brazil;(14)Clinica ESADI, Gastroenterology, Blumenau, Brazil;(15)Kaiser Clínica, Colorectal Surgery, Sao Jose do Rio Preto, Brazil;(16)Hospital Santa Cruz, Gastroenterology, Curitiba, Brazil;(17)Kaiser Clinica, Colorectal Surgery, Sao Jose do Rio Preto, Brazil;(18)Universidade Federal do Paraná, Colorectal Surgery, Curitiba, Brazil;(19)Universidade Estadual da Bahia, Gastroenterology, Salvador, Brazil;(20)Pontificia Universidade Católica do Paraná PUCPR, IBD outpatient Clinics, Curitiba, Brazil;
P587: Intestinal ultrasound (IUS) and magnetic resonance imaging (MRI) for monitoring of response to therapy in luminal Crohn's disease – a systematic review.ECCO’23 CopenhagenYear: 2023
Authors: Lovett, G.(1,2)*;Schulberg, J.D.(1,2);Hamilton, A.L.(1,2);Wilding, H.E.(3);Kamm, M.A.(1,2);Wright, E.K.(1,2);
(1)St Vincent's Hospital Melbourne, Department of Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Department of Medicine, Melbourne, Australia;(3)St Vincent's Hospital Melbourne, Library Service, Melbourne, Australia;
P588: Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Jairath, V.(1,2,3)*;Zou, G.(2,3,4);Wang, Z.(3);Adsul, S.(5);Colombel, J.F.(6);D'Haens, G.R.(7);Freire, M.(5);Moran, G.W.(8,9);Peyrin-Biroulet, L.(10);Sandborn, W.J.(11);Sebastian, S.(12,13);Travis, S.(14);Vermeire , S.(15);Radulescu, G.(3);Sigler, J.(3);Mcfarlane, S.(3);Arya, N.(16);Beaton, M.(1);Bossuyt, P.(17);Green, D.(18);Harlan III, W.(19);Horynski, M.(20);Klopocka, M.(21,22);Petroniene, R.(23);Silverberg, M.S.(24);Wolanski, L.(25);Feagan , B.G.(1,2,3);
(1)University of Western Ontario, Department of Medicine- Division of Gastroenterology, London, Canada;(2)University of Western Ontario, Department of Epidemiology and Biostatistics, London, Canada;(3)Alimentiv Inc., Medical Research and Development, London, Canada;(4)University of Western Ontario, Robarts Research Institute- Schulich School of Medicine and Dentistry, London, Canada;(5)Takeda Pharmaceuticals, Medical, Cambridge, United States;(6)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(7)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(8)University of Nottingham, Nottingham Digestive Diseases Biomedical Research Centre, Nottingham, United Kingdom;(9)Nottingham University Hospitals NHS Trust, NIHR Nottingham Biomedical Research Centre, Nottingham, United Kingdom;(10)Inserm NGERE U1256- University Hospital of Nancy- University of Lorraine, Department of Gastroenterology, Vandoeuvre-lès-Nancy, France;(11)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(12)Hull Royal Infirmary, Hull and East Yorkshire NHS Trust & Hull and York Medical School, Hull, United Kingdom;(13)Hull York Medical School, School of Health & Life Sciences, Hull, United Kingdom;(14)University of Oxford, Kennedy Institute and Biomedical Research Centre, Oxford, United Kingdom;(15)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(16)ABP Research Services Corp., Gastroenterology, Oakville, Canada;(17)Imelda General Hospital, Imelda GI Clinical Research Center, Bonheiden, Belgium;(18)Taunton Surgical Centre, Department of Gastroenterology, Oshawa, Canada;(19)Asheville Gastroenterology Associates, Gastroenterology, Asheville, United States;(20)Endoskopia Sp. z.o.o., Gastroenterology, Sopot, Poland;(21)Collegium Medicum- Nicolaus Copernicus University, Department of Gastroenterology and Nutritional Disorders, Bydgoszcz, Poland;(22)Dr. Jana Biziel University Hospital n 2 in Bydgoszcz, Gastroenterology Clinic, Bydgoszcz, Poland;(23)Barrie GI Associates Inc., Gastroenterology, Barrie, Canada;(24)Toronto Immune and Digestive Health Institute, Gastroenterology, Toronto, Canada;(25)Independent Public Healthcare Center in Łęczna, Gastroenterological Department, Łęcznej, Poland;on behalf of the VERDICT Study Group
P589: Effectiveness of partial enteral nutrition to treat adults with Crohn's Disease who lost response to biological therapyECCO’23 CopenhagenYear: 2023
Authors: Nardone, O.M.(1)*;Calabrese, G.(2);Alfonsi, L.(3);Rispo, A.(2);La Mantia , A.(2);Fierro, G.(2);Ferrante, M.(2);Testa, A.(2);Guarino, A.D.(2);D'Alessandro, E.(2);Pasanisi, F.(3);Castiglione, F.(2);
(1)University Federico II of Naples, Gastroenterology- Department of Public Health, Naples, Italy;(2)University Federico II of Naples, Gastroenterology- Department of Clinical Medicine and Surgery, Naples, Italy;(3)University Federico II of Naples, Internal Medicine and Clinical Nutrition-Department of Clinical Medicine and Surgery, Naples, Italy;
P590: ADVANCED-UC TRIAL: AppenDectomy Vs ANti TNF-a in inducing Clinical and EnDoscopic remission in left-sided Ulcerative Colitis – A Randomized Clinical TrialECCO’23 CopenhagenYear: 2023
Authors: Luglio, G.(1)*;Rispo, A.(2);Tropeano, F.P.(3);Cricrì, M.(2);Castiglione, F.(2);De Palma, G.D.(2);
(1)University of Naples Federico II, Department of Public Health, Napoli, Italy;(2)University of Naples Federico II, Department of Clinical Medicine and Surgery, Naples, Italy;(3)University of Naples Federico II, Department of Advanced Biomedical Sciences, Naples, Italy;
P591: Negative impact of high body mass index on the efficacy of anti-TNFα agents in patients with Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Hamoir, F.(1)*;De Leuze, F.(1);Denis, M.(1);De Vroey, B.(1);De Suray, N.(1);Burnet, G.(1);Piessevaux, H.(1);Dewit, O.(1);
(1)Cliniques Universitaires Saint-Luc, Gastro-enterology, Brussels, Belgium;
P592: Clinical evaluation of leukocytapheresis compared to vedolizumab in patients with Ulcerative Colitis with contraindications to anti-TNF-alpha: a single-centre experienceECCO’23 CopenhagenYear: 2023
Authors: Ferronato, A.(1)*;Rigno, M.(2);Rodriguez-Castro, K.I.(1);Brozzi, L.(1);Errigo, G.(2);Castelli, M.(2);Baldassarre, G.(1);
(1)Endoscopy Unit Az. ULSS 7 Pedemontana, Medicine, Santorso VI, Italy;(2)Transfusion Medicine Unit Az. ULSS 8 Berica, Diagnostics, Vicenza, Italy;
P593: Impact of immunomodulating treatment modalities, active smoking and (repeated) COVID19 vaccination on S-antibody seroconversion in IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)ECCO’23 CopenhagenYear: 2023
Authors: Geldof, J.(1)*;Truyens, M.(2);Sabino, J.(3);Ferrante, M.(3);Lambert, J.(4);Lapeere, H.(4);Hillary, T.(5);Van Laethem, A.(5);de Vlam, K.(6);Verschueren, P.(6);Padalko, E.(7);Lobaton, T.(2);Vermeire, S.(3);
(1)Ghent University Hospital, Department of Gastroenterology and Hepatology, Gent, Belgium;(2)Ghent University Hospital, Department of Gastroenterology and Hepatology, Ghent, Belgium;(3)University Hospitals Leuven, Department of Gastroenterology and Hepatology- Translational Research in Gastrointestinal Disorders TARGID and Department of Chronic Diseases and Metabolism CHROMETA KU Leuven, Leuven, Belgium;(4)Ghent University Hospital, Department of Dermatology, Ghent, Belgium;(5)University Hospitals Leuven, Department of Dermatology, Leuven, Belgium;(6)University Hospitals Leuven, Department of Rheumatology, Leuven, Belgium;(7)Ghent University Hospital, Department of Laboratory Medicine, Ghent, Belgium;BELCOMID study group
P594: Bowel ultrasound is useful in predicting relapse in patients with Ulcerative Colitis in remissionECCO’23 CopenhagenYear: 2023
Authors: Maeda, M.(1)*;Sagami, S.(1,2);Tashima, M.(1);Yamana, Y.(1);Karashima, R.(1,2);Miyatani, Y.(1);Hojo, A.(1,2);Nakano, M.(1,2);Hibi, T.(1);Kobayashi, T.(1,2,3);
(1)Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan;(2)Department of Gastroenterology, Kitasato University Kitasato Institute Hospital, Tokyo, Japan;(3)Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan;
P595: Time of Therapeutic Drug Monitoring of infliximab during induction and its relationship with clinical remission in Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Muñoz-Villafranca, C.(1);Arreba , P.(1);Gomez, M.(2);Ispizua Madariaga, N.(1)*;Buendia, L.(1);Lopez, M.L.(1);Ugarte, A.(1);de la Fuente, I.(1);Prado, N.(1);Irusta, L.(1);Jimenez, M.A.(1);Santa Cruz, M.(1);Gonzalez, M.(1);Bilbao, A.(3);Ortiz de Zárate, J.(1);
(1)Hospital Universitario Basurto, Gastroenterology, Bilbao, Spain;(2)Hospital de San Eloy, Gastroenterology, Baracaldo, Spain;(3)Hospital Universitario Basurto, Research unit, Bilbao, Spain;
P596: Ustekinumab and anti-TNF agents are equally safe and effective in elderly Crohn's disease patients: A propensity adjusted multi-centre cohort studyECCO’23 CopenhagenYear: 2023
Authors: Gebeyehu, G.G.(1);Broglio, G.(2);Liu, E.(3);Limdi, J.K.(4);Selinger, C.(5);Fiske, J.(1);Razsanskaite, V.(1);Smith, P.J.(1);Flanagan, P.K.(6);Subramanian, S.(7)*;
(1)Liverpool University Hospitals NHS Foundation Trust, Department of Gastroenterology, Liverpool, United Kingdom;(2)IRCCS San Matteo of Pavia- University of Pavia, Department of Internal Medicine, Pavia, Italy;(3)Northern Care Alliance NHS Trust, Section of IBD - Division of Gastroenterology, Manchester, United Kingdom;(4)University of Manchester, Manchester Academic Health Sciences - Faculty of Medicine, Manchester, United Kingdom;(5)Leeds University Teaching Hospital NHS Trust, Department of Gastroenterology, Leeds, United Kingdom;(6)Wirral University Teaching Hospital NHS Trust, Department of Gastroenterology, Wirral, United Kingdom;(7)Cambridge University Hospital NHS Foundation Trust, Department of Gastroenterology, Cambridge, United Kingdom;
P597: Usefulness of histological monitoring in predicting relapse after de-escalation of thiopurines in Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Yamana, Y.(1)*;Sagami, S.(1);Maeda, M.(1);Karashima, R.(1);Miyatani, Y.(1);Hojo, A.(1);Nakano, M.(1);Maeda, I.(2);Hibi, T.(1);Kobayashi, T.(1,3);
(1)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(2)Kitasato University Kitasato Institute Hospital, Department of Diagnostic Pathology, Tokyo, Japan;(3)Kitasato University School of Medicine, Department of Gastroenterology, Kanagawa, Japan;
P598: The utility of the “Low Anterior Resection Syndrome SCORE” in assessing the postoperative outcomes of patients undergoing restorative proctocolectomy with ileal pouch anal-anastomosis for Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Perotti, S.(1)*;Mineccia, M.(1);Daperno, M.(2);Massucco, P.(1);Gonella, F.(1);Ferrero , A.(1);
(1)Ospedale Mauriziano "Umberto I", General and Oncological Surgery, TORINO, Italy;(2)Ospedale Mauriziano "Umberto I", Gastroenterological and Endoscopic Department, Torino, Italy;
